|
?:definition
|
-
A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-brachyury vaccine, the vector expresses the brachyury protein. The expressed brachyury protein may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury. The MVA-BN-brachyury vaccine, which is a priming vaccine, is followed by multiple boosting doses of the fowlpox virus (FPV)-brachyury vaccine. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation. Check for \'https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C148400\' active clinical trials using this agent. (\'http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C148400\' NCI Thesaurus)
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}